Denosumab is administered as a subcutaneous injection. The recommended dose for the prevention of SREs in patients with bone metastases is 120 mg every four weeks. For the treatment of giant cell tumor of bone, it is given at a dose of 120 mg every four weeks with additional doses on days 8 and 15 during the first month of therapy.
